Seroprevalence of SARS-CoV-2 (COVID-19) among Healthcare Workers in Saudi Arabia: Comparing Case and Control Hospitals by Alserehi, Haleema Ali et al.
Seroprevalence of SARS-CoV-2 (COVID-19) among Healthcare Workers in Saudi Arabia: 
Comparing Case and Control Hospitals 
Haleema Ali Alserehi1*, Ada Mohammed Alqunaibet1, Jaffar A. Al-Tawfiq2,3,4*, Naif Khalaf 
Alharbi5,6, Abeer Nizar Alshukairi7, Khalid Hamdan Alanazi8, Ghada Mohammed Bin Saleh8, 
Amer Mohammed Alshehri9, Abdulrahman Almasoud5, Anwar M. Hashem10,11, Amaal Rabie 
Alruwaily1, Rehab Habeeb Alaswad1, Hind Mohammed Al-Mutlaq1, Abdulllah Ali 
Almudaiheem1, Fatmah Mahmoud Othman12, Sumyah Abdullah Aldakeel9 , Mouath Rashid 
Abu Ghararah9 ,Hani Abdulaziz Jokhdar13, Abdullah Rshoud Algwizani14, Sami Saeed 
Almudarra1, Ahmed Mohammed Albarrag9,15 
1Executive Department of Global Health, Epidemiology, surveillance and preparedness 
affairs, Executive Department of Research, Saudi Center for Disease Prevention and Control, 
Riyadh, Saudi Arabia; 2Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins 
Aramco Healthcare, Dhahran, Saudi Arabia, 3Department of Medicine, Indiana University 
School of Medicine, Indianapolis, IN, USA; 4Department of Medicine, Johns Hopkins 
University School of Medicine, Baltimore, MD, USA; 5Vaccine Development Unit, 
Department of Infectious Disease Research, King Abdullah International Medical Research 
Center, Riyadh, Saudi Arabia, 6King Saud bin Abdulaziz University for Health Sciences, 
Riyadh, Saudi Arabia 7Department of medicine, King Faisal Specialist Hospital and Research 
Center, Jeddah, Saudi Arabia; 8Infection and Control Department, Ministry of Health, Riyadh, 
Saudi Arabia; 9Public Health Lab, Saudi Center for Disease Prevention and Control, Riyadh, 
Saudi Arabia; 10 Department of Medical Microbiology and Parasitology, Faculty of Medicine, 
_______________________________________________
This is the author's manuscript of the article published in final edited form as:
Alserehi, H. A., Alqunaibet, A. M., Al-Tawfiq, J. A., Alharbi, N. K., Alshukairi, A. N., Alanazi, K. H., ... & Albarrag, A. M. (2020). 
Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: comparing case and control hospitals. Diagnostic 
microbiology and infectious disease, 99(3), 115273.  https://doi.org/10.1016/j.diagmicrobio.2020.115273
2 
 
King Abdulaziz University, Jeddah, Saudi Arabia;11Vaccines and Immunotherapy Unit, King 
Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; 12Research 
department, College of Applied Medical Sciences, King Saud bin Abdulaziz University for 
Health Sciences, Riyadh, Saudi Arabia; 13Public Health, Ministry of Health, Riyadh, Saudi 
Arabia; 14Saudi Cenetr for Disease Control and Prevention, Riyadh, Saudi Arabia; 
15Department of Pathology, School of Medicine, King Saud University, Riyadh, Saudi Arabia 
 
Correspondence: 
Dr. Haleema Ali Alserehi* 
1Executive Department of Global Health,Saudi Center for Disease Prevention and Control, 
Riyadh, Saudi Arabia 
E-mail: dr al serihi@hotmail.com, halserehi@moh.gov.sa 
AND 
Dr. Jaffar A. Al-Tawfiq* 
Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia. 
E-mail address: jaffar.tawfiq@jhah.com; jaltawfi@yahoo.com 
Tel: +966-13-870-3524; Fax: +966-13-870-3790 
Abstract: 
Background: Healthcare workers (HCWs) stand at the frontline for fighting coronavirus 
disease 2019 (COVID-19) pandemic. This puts them at higher risk of acquiring the infection 
than other individuals in the community. Defining immunity status among health care 
workers is therefore of interest since it helps to mitigate the exposure risk. 
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Study Design: Eighty-five hospitals across KSA were divided into two groups: COVID-19 
referral hospitals are those to which RT-PCR-confirmed COVID-19 patients were admitted or 
referred for management (Case-hospitals). COVID-19 non-affected hospitals where no 
COVID-19 patients had been admitted or managed and no HCW outbreak (Control 
hospitals). Next, seroprevalence of SARS-CoV-2 among healthcare workers (HCWs) was 
evaluated; there were 12,621 HCWs from the 85 hospitals.   
Result: There were 61 case-hospitals with 9,379 (74.3%) observations, and 24 control-
hospitals with 3,242 (25.7%) observations. The overall positivity rate by the immunoassay 
was 299 (2.36%) with a significant difference between the case-hospital (2.9%) and the 
control-group (0.8%) (P value <0.001).  There was a wide variation in the positivity rate 
between regions/cities in Saudi Arabia, ranging from 0% to 6.31%. Of the serology positive 
samples, 100 samples were further tested using the SAS2pp neutralisation assay; 92 (92%) 
samples showed neutralisation activity.   
Conclusion: The seropositivity rate in KSA is low and varies across different regions with 
higher positivity in case-hospitals than control-hospitals.  The lack of NAb in 8% of the tested 
samples could mean that assay is a more sensitive assay or that neutralisation assay has a 
lower detection limits; or possibly that some samples had cross-reaction to spike protein of 
other coronaviruses in the assay, but these were not specific to neutralize SARS-CoV-2.   
Introduction: 
Healthcare workers (HCWs) stand at the frontline for fighting coronavirus disease 2019 
(COVID-19) pandemic. This puts them at higher risk of acquiring the infection than other 
individuals in the community (Ferioli et al. 2020).  Several hospitals, since the beginning of 
this pandemic, have implemented strategies to protect their healthcare workers that 
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include, but not limited to, providing adequate personal protective equipment, weekly shifts 
system, period screening of their staff, and other IPC measures (Al-Tawfiq et al. 2020; 
Barranco and Ventura 2020; Galan et al. 2020).  Since the global emergence of this 
pandemic, in March 2020, many health care settings have started to report the burden of 
COVID-19 infection among their healthcare workers (Barranco and Ventura 2020; Folgueira 
et al. 2020; Wei et al. 2020). However, reporting only symptomatic and infected cases 
among HCWs could lead to a significant underestimation of the prevalence of severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Thus, many reports indicate the 
presence of subclinical infection among healthcare workers, which impose threaten risk to 
other patients, co-workers, and families (Ferioli et al. 2020; Korth et al. 2020a). Defining 
immunity status among health care workers, therefore, is of interest since it helps to 
mitigate the exposure risk. 
The evidence on COVID-19 infection among healthcare workers is growing in which several 
studies have estimated the seroprevalence of SARS-CoV-2 among their healthcare workers. 
The results of those studies indicate that between 1.7 to 11% of healthcare workers were 
seropositive (Brandstetter et al. 2020; Folgueira et al. 2020; Galan et al. 2020; Garcia-
Basteiro and Gemma Moncunill, Marta Tortajada, Marta Vidal, Caterina Guinovart, Alfons 
Jimenez, Rebeca Santano, Sergi Sanz, Susana Mendez, Anna Llupia, Rugh Aguilar, Selena 
Alonso, Diana Barrios, Carlo Carolis, Pau Cistero, Eugenia Choliz, A 2020; Paderno et al. 
2020a). Importantly, a number of those studies reported the occurrence of seropositivity 
among individuals who did not report any symptoms by 38-48% (Folgueira et al. 2020; Galan 
et al. 2020; Garcia-Basteiro and Gemma Moncunill, Marta Tortajada, Marta Vidal, Caterina 
Guinovart, Alfons Jimenez, Rebeca Santano, Sergi Sanz, Susana Mendez, Anna Llupia, Rugh 
Aguilar, Selena Alonso, Diana Barrios, Carlo Carolis, Pau Cistero, Eugenia Choliz, A 2020). The 
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advantages of seroprevalence studies rely on the usefulness of such a method to assess the 
level of subclinical exposure among cases and identify high-risk groups (Al-Tawfiq and 
Memish 2020).  The aim of the study was to evaluate seroprevalence of SARS-CoV-2 
antibodies among HCW in various hospitals in the Kingdom of Saudi Arabia (KSA) and to 
compare seroprevalence between HCWs in hospitals caring for COVID-19 cases and other 
hospitals.   
Materials and Methods: 
Study Population: The study included hospitals with more than 200 beds. Study hospitals 
were divided into two groups: COVID-19 referral /affected hospitals are those to which RT-
PCR-confirmed COVID-19 patients were admitted or referred for management (Case-
hospitals). COVID-19 non-affected hospitals where no COVID-19 patients had been admitted 
or managed and no HCW outbreak (Control hospitals).  We aimed to include 12000 HCWs 
with a Case Control ratio of 2:1. HCWs who agreed to participate signed consents for 
participation.  Health workers included physicians, nurses, pharmacists, respiratory 
therapists, and administrative support who agree to participate in the study.  The HCWs 
were from departments at high risk to get exposed to COVID 19 cases: medicine, intensive 
care units and emergency departments.  We excluded HCWs who were experiencing any 
symptoms of COVID-19 at the time of enrolment. 
Specimens were transported to the Saudi CDC Lab. Samples were transported and delivered 
within 48 hr at 4-80C.  When serum samples were not processed immediately, sera were 
stored at -80°C. Serological testing: Serum samples were screened for the presence of SARS-
CoV-2 antibodies using a chemiluminescent microparticle immunoassay (CMIA) which 
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detects IgG raised against the nucleocapsid protein of SARS-CoV-2. (Abbott Architect SARS-
CoV-2 IgG kit, Abbott, USA). 
SARS-CoV-2 pseudotyped viral particles (SARS2pp) neutralisation assay: SARS-CoV-2 
pseudotyped viral particles (SARS2pp) were produced in HEK293T cells and titrated using 
Huh7.5 cells as described for MERSpp previously (Grehan et al. 2015; Alharbi et al. 2019; 
Almasaud et al. 2020).  Here, 100 samples that were positive by immunoassay (one third of 
the positive samples) were prepared in a 1:20 and 1:40 dilutions to assess their 
neutralisation activity (percent). In addition, 20 of these 100 samples were prepared in eight 
serial dilutions (3-fold) starting from 1:20, and tested for nAbs titre in duplicates. 
 A standard concentration of SARS2pp (equivalent to 200,000 RLU) and Huh7.5 cells (10,000 
cells) were added to each well of 96-well opaque plate. Cells only and cells-plus-SARS2pp 
only (both without serum) were included in quadruplicate as controls to determine 0% and 
100% neutralisation activity, respectively. Following 48 h incubation, cells were lysed and 
the assay was developed using Bright-Glo™ Luciferase Assay System (Promega, USA) and 
luciferase activity was measured using a luminometer. Samples were considered positive if 
neutralisation activity was detected in both dilutions (1:20 and 1:40) and the neutralisation 
percent was reported as compared to cell-plus-SARS2pp control. For 20 samples, a further 
evaluation of the NAb titres (IC50 neutralisation titres) were calculated for each serum 
sample across 8 dilutions and plotted using GraphPad Prism. 
The study was approved by the Saudi Ministry of health IRB (H-01-R-009). 
Statistical Method: 
Our descriptive analysis included counts and proportions for categorical variables. 
For bivariable analysis, the Chi-square test was conducted to assess the association between 
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Serology test and Case-control hospitals. Another Chi-square test was conducted to assess 
the association between regions and the serology test. We employed logistic regression 
models to examine the relationship between the outcome Serology test and the exposure 
Case-control hospitals, and the relationship between the outcome serology test and the 
exposure Regions. The magnitude of association presented as the odds. All reported 95% CI 
and P-values in the two models were based on the logistic regression. We used STATA 15.1 
to perform all of the analysis. The significance level for all of the statistical tests was set at 
0.05. 
Results: 
During the study period, there were 12,621 HCWs from 85 hospitals. There were 61 
case-hospitals with 9,379 (74.3%) HCWs, and 24 control-hospitals with 3,242 (25.7%) HCWs. 
The overall positivity rate by immunoassay was 299 (2.36%) of the total 12621 HCWs.  Out 
of the 299 seropositive HCWs, 86 (28.7%) were positive by PCR for SARS-CoV-2.  However, 
none was symptomatic as we excluded symptomatic HCWs from the study.  There was a 
significant difference in the positivity rate between case-hospitals (2.9%) and the control-
hospitals (0.8%) with a crude Odd Ratio of 3.71 (95% CI; 2.47-5.55) (P value <0.001). There 
was a wide variation in the positivity rate between regions/cities in Saudi Arabia from 0% to 
6.31% (Table 2). The highest rate of positivity was in Makkah (6.31%, OR 6.3) and Al-
Madinah Al-Mounawarah (4.55%, OR 4.46); followed by the Eastern Region (1.55%, OR 
1.47), Aseer (2.18%, OR 2.08). The crude Odd Ratio based on Riyadh (1.06% positivity rate) is 
also shown. 
To confirm that the immunoassay test is reliable in detecting anti-SARS-CoV-2 IgG 
antibodies, 100 seropositive samples (1/3 of the total positive samples) were randomly 
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selected for further testing using the SAS2pp neutralisation assay. Of these samples, 92 
(92%) samples showed neutralisation activity; 76 of which had higher than 50% 
neutralisation at 1:40 dilution (Figure 1).  Additionally, 20 of the 100 samples were further 
evaluated to report the IC50 NAb titres (Figure 2). Some of these sera did not show NAb 
indicating that they could have a low level of NAb that could not be determined by the 
SAS2pp neutralisation assay or that these samples have antibodies against related 
coronaviruses and might have cross-reacted with the spike antigen in immunoassay.  
Discussion: 
COVID-19 is an emerging disease caused by the SARS-CoV-2 and was declared as a 
pandemic in March 2020.  The first case of COVID-19 was reported in Saudi Arabia on March 
2nd, 2020 and the current study was conducted between May 20th and 30th, 2020 at the 
times when the Kingdom of Saudi Arabia had 62,000-80,000 cases.  The study was 
conducted just before the peak of cases in the country.  Being front liners in the control of 
the disease, HCWs represent 3.5% to 16% of all cases in China and USA respectively 
(Europenan Center for Disease Control and Prevention). Previously, there were several 
MERS-CoV hospital outbreaks described in KSA (Al-Tawfiq and Auwaerter 2019).  The most 
important sero-epidemiological study among HCW has shown that 20 out of 250 cases were 
diagnosed by serology with various attack rate between various departments based on 
extent of exposure to MERS (Alraddadi et al. 2016) and only 25% of cases had positive PCR. 
There is one report describing the seroprevalence of MERS-CoV among HCWs during the 
Korean outbreak with a seropositivity of 0.7% in HCW who did not use personal protective 
equipment (PPE) and 0% in those who used PPE (Kim et al. 2016).  With the ongoing 
outbreak and concern of asymptomatic transmission, several asymptomatic HCWs can 
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infect patients in addition several asymptomatic patients can infect HCW. With the 
increasing number of HCWs that are isolated at home following exposure to COVID-19 cases 
and with the increasing number of COVID-19 patients requiring more care from HCWs, 
better strategies were suggested to assess the immunity of HCWs to protect both patients 
and HCWs; especially that the COVID-19 PCR testing may have detection limitations. 
At the national level, studying the prevalence of SARs-CoV-2 among Saudi healthcare 
workers is important to understand the exposure risk among this population, and to 
compare different risk factors of the infection, which can influence infection control 
measures and policies.  Our aim was to study the seroprevalence of COVID-19 among HCW 
in various hospitals in KSA using a screening serological tests followed by a confirmatory 
neutralization test. However, it may be important to note that screening serological tests 
are lacking specificity as advised by the WHO. 
 In this study the overall rate of positive serology was 2.3% among HCWs. In a study 
in Tennessee, USA, of 249 front-line HCWs who cared for COVID-19 patients, 8% tested 
positive for COVID-19 antibodies by serology (Stubblefield et al. 2020a).  In a study of 2507 
HCWs in Italy, the positivity rate was 0% for IgM and 0.7% for IgG antibodies (Lahner et al. 
2020).  We observed a higher positivity rate among case-hospitals of 2.9% vs 0.8% in the 
control hospitals. Thus, the overall rate of IgG positivity in this study is 3.3 times that seen in 
the study from Italy. However, there is a variable rate of positivity among HCWs 
worldwide(Barrett et al. 2020; Brandstetter et al. 2020; Folgueira et al. 2020; Galan et al. 
2020; Garcia-Basteiro and Gemma Moncunill, Marta Tortajada, Marta Vidal, Caterina 
Guinovart, Alfons Jimenez, Rebeca Santano, Sergi Sanz, Susana Mendez, Anna Llupia, Rugh 
Aguilar, Selena Alonso, Diana Barrios, Carlo Carolis, Pau Cistero, Eugenia Choliz, A 2020; 
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Hains et al. 2020; Korth et al. 2020a; Paderno et al. 2020b; Sandri et al. 2020). Antibody 
response may be related to the level of exposure in hospitals as exemplified by the 
differences in the control-hospitals versus the case-hospitals in this study. In an Infectious 
Diseases specialized setting in Naples, Southern Italy, antibody seroprevalence was 1.7% 
among tested HCWs (Fusco et al. 2020), indicating low rate despite the possible high 
exposure. Therefore, additional explanations is required; and this might be because of the 
short-lived antibody response or the timing of the antibody tests post exposure (Seow et al. 
2020). 
 The study showed variable seroprevalence in different regions. Case-hospitals were 
also more likely to have positive serology compared to the control-hospitals. Although most 
of the control hospitals were in the regions where the number of cases is low, control 
hospitals from regions with higher community cases were also included.  Multiple factors 
may play a role in the occurrence of higher seroprevalence among the HCW in the case-
hospitals at different regions.  One factor is of course the number of COVID-19 cases in 
these hospitals.  Another factor is the number of COVID-19 cases in the community.  As 
indicated above, this study was conducted between May 20th and 30th, 2020 at the time 
when the Kingdom had 62,000-80,000 cases. And there were different positivity rates and 
cases between the different regions at that time. Of the total reported cases at that time, 
Makkah region accounted for 41% of all the reported cases indicating a higher prevalence of 
cases in the region.   In addition, 15% of the cases were in Madinah, 20% in Riyadh, 19% in 
the eastern region and less than 2% in other regions.  There was a high number of 
community cases in the regions that have high HCW seroprevalence for COVID-19 such as 
what was seen in Makkah and Madinah compared to Riyadh and Eastern region.  There 
were relatively high number of community cases in Riyadh and Eastern province but these 
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showed low HCW seroprevelance.  The findings suggest that the high seroprevalence may 
be secondary to community exposure although other factors cannot be excluded such 
hospital environment and compliance with infection control measures.  One study showed 
that HCW positivity for SARS-CoV-2 was associated with working in COVID-19 units, 
(RR = 2.449, confidence interval = 1.062-5.649, P= .027), a positive household, inappropriate 
use of PPE, having a break in the same personnel break room as an HCW without a medical 
mask for more than 15 minutes, consuming food within 1 m of an HCW, and non-
compliance with safe social distancing (Çelebi et al. 2020).  It was found that exposure of 
HCWs to SARS-CoV-2 may be in the hospital, from household members, or community-
acquired (Burrer et al. 2020).  In one study, 137 (27%) of 500 HCW were positive for SARS-
CoV-2 antibody with much higher rate among symptomatic participants (75%) and of all the 
positive HCWs 34% had community exposure (Venugopal et al. 2020).  Seroprevalence is 
also related to the level of HCWs exposure and one study showed that seroprevalence was 
higher in an intermediate-risk-group vs. high-risk-group (5.4 % vs. 1.2 %) (Korth et al. 2020b).  
Another study showed that enzyme immunoassay (EIA) and microneutralization assay were 
positive in 17.14% (18/105) of HCWs who were contacts of COVID-19 patients despite 
negative SARS-CoV-2 (Chen et al. 2020).  The risk of seropositivity was lower with wearing 
face mask (odds ratio [OR], 0.127, 95% confidence interval [CI] 0.017, 0.968) (Chen et al. 
2020).  We showed that HCWs working in case-hospitals had higher positivity rate and this 
was similar to a study that showed 19 (7.6%) of 249 HCWs who worked in COVID-19 units for 
one month were positive (Stubblefield et al. 2020b).  However, in another study of 202 HCWs 
the positivity rate was 14.4% for IgM and 7.4% for IgG with no relationship to COVID-19 
exposure (Sotgiu et al. 2020).  It was interesting to note that one study showed similar 
seropositivity among HCWs with heavy and low COVID-19 exposure (Hunter et al. 2020).  
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Thus, a multi-centre study is needed to elucidate carefully factors contributing to the 
seropositivity of HCWs to SARS-CoV-2.  Such identification would aid in better 
understanding and facilitate the introduction of preventive measures for HCWs. 
The lack of NAb in 8% of the tested samples could mean that assay is a more 
sensitive or that neutralisation assay has a lower detection limit. It could possibly be that 
some sera had cross-reactive antibodies to the spike protein in the serological assay 
originating from an exposure to other coronaviruses; especially that MERS is endemic in 
Saudi Arabia and the asymptomatic rate of MERS infections in understudied. The ELISA or 
CMIA assays are not 100% specific and positive reactions were obtained for subjects with 
antibodies against other coronaviruses.  The assay used is a chemiluminescent microparticle 
immunoassay (CMIA) with higher specificity compare to ELISA.  The specificity of the assay 
based on the available studies is 99.2 -100% (Bryan et al. 2020; Perkmann et al. 2020; Public 
Health England 2020). The tested samples without Nab activities is more likely to have lower 
level of antibody titre to be detected by Nab assay or that these samples have antibodies 
against related coronaviruses and might have cross-reacted with the spike antigen in 
immunoassay.  
This study is the first seroprevalence of HCWs in Saudi Arabia.  Few weaknesses are 
possible.  The hospitals were classified based on the available national surveillance data 
(National Health electronic surveillance system).  The control hospitals implemented the 
same criteria and indication for COVID-19 testing as the case hospitals. Indications for 
repeating the test were similar in both groups of hospital. Control Hospitals were defined as 
COVID-19 non-affected hospitals as there was no management of COVID-19 patients and 
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there were no COVID-19 outbreaks among HCWs.  And thus we could not exclude 
completely the diagnosis of a single COVID-19 case in the control hospital.  
In conclusion, this is a national serosurvey of SARS-CoV-2 among HCWs working in hospitals 
with and without COVID-19 patients.  The study was based on a random sample of HCWs.  
Since the duration of detectable antibodies is variable no recommendation can be 
generated for those who have negative SARS-COV2 antibodies.  The findings may indicate a 
large number of HCWs are still at high risk of acquiring infection in different setting and thus 
strong strategies are need to strengthen infection control measures, and to continue to 
have staff training.  We included  
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Tables and Figures: 
Table 1: Rate of Positive serological assay between Control-group and Case-hospital 
among Healthcare Workers. 
Total Positive Percent positive 
Control 3,242 26 0.8 
Case 9,379 273 2.9 
Total 12,621 299 2.36 
Pearson chi2(1) =  44.2698   P = 0.0001 
Table 2: Percentage of positivity rate among Healthcare Workers in relation to the 
Region/City in Saudi Arabia 






Hail 1 0.2 501 
0.18 0.02 1.36 0.099 
Najran 1 0.23 437 
0.21 0.02 1.56 0.13 
Baha 1 0.34 296 
0.31 0.04 2.32 0.258 
Qassim 2 0.39 513 
0.36 0.08 1.52 0.168 
Northern Border 1 0.65 154 
0.61 0.08 4.49 0.629 
Jazan 3 0.67 447 
0.63 0.19 2.06 0.447 
Riyadh 36 1.06 3,405 
1 
Eastern Region 29 1.55 1,869 
1.47 0.9 2.41 0.122 
Aseer 19 2.18 870 
2.08 1.19 3.66 0.01 
Madinah 37 4.55 813 
4.46 2.8 7.1 <0.001 
Makkah 169 6.31 2,678 
6.3 4.38 9.06 <0.001 
22 
Total 299 2.37 12,621 
Figure 1:  Neutralisation assay (NA) was performed based on SARS-CoV-2 pseudotyped 
viral particles (SARS2pp).  
A: Neutralisation percentage of serum samples (n=100) that were diluted 1:40 and run in 
SARS2pp NA. Dotted line shows 50% neutralisation activity. B: Some serum samples (n=20) 
were further tested in SARS2pp NA in a 3-fold serial dilution to present the titre nAb as 50% 
inhibitory concentration (IC50). 
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